Materials Today Bio,
Год журнала:
2025,
Номер
unknown, С. 101634 - 101634
Опубликована: Март 1, 2025
The
response
rate
of
programmed
cell
death
protein-1
(PD-1)
inhibitors
in
breast
cancer
remains
unsatisfactory,
primarily
due
to
the
limited
infiltration
and
activity
tumor-infiltrating
T
lymphocytes
(TILs).
Previous
studies
demonstrated
that
oxymatrine
(Om)
astragaloside
IV
(As)
could
enhance
TIL
function
by
inhibiting
cancer-associated
fibroblasts
(CAFs)
promoting
mitochondrial
TILs,
respectively.
Thus,
combining
Om
As
may
be
a
promising
strategy
improve
antitumor
effects
PD-1
cancer.
However,
co-delivery
above
drugs
into
tissue
is
challenging
their
low
bioavailability
distinct
physicochemical
properties.
This
study
addresses
this
challenge
formulating
co-loaded
liposomes
(Om-As-Lip)
comparing
scale-up
production
methods:
high-pressure
homogenization
(EP-HPH)
microfluidics.
Om-As-Lip
prepared
via
microfluidics
superior
entrapment
efficiency
(As:
99.03
±
0.04
%,
Om:
67.01
0.02
%)
significantly
higher
(22.12
mL/min)
compared
EP-HPH
(1.19
mL/min).
Additionally,
produced
increased
area
under
curve
(AUC)
(Om:
6.17-fold,
As:
2.07-fold)
maximum
concentration
(Cmax)
1.58-fold,
3.49-fold)
free
drugs.
Importantly,
enhanced
efficacy
α-PD-1
CAF
activation
boosting
activity,
resulting
tumor
inhibition
61.2
%
extended
survival
mice.
work
presents
novel
perspective
for
scaling
up
co-delivered
formulations
with
differing
polarities
immunotherapy.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Авг. 12, 2024
Cancer
remains
a
significant
risk
to
human
health.
Nanomedicine
is
new
multidisciplinary
field
that
garnering
lot
of
interest
and
investigation.
shows
great
potential
for
cancer
diagnosis
treatment.
Specifically
engineered
nanoparticles
can
be
employed
as
contrast
agents
in
diagnostics
enable
high
sensitivity
high-resolution
tumor
detection
by
imaging
examinations.
Novel
approaches
labeling
are
also
made
possible
the
use
nanoprobes
nanobiosensors.
The
achievement
targeted
medication
delivery
therapy
accomplished
through
rational
design
manufacture
nanodrug
carriers.
Nanoparticles
have
capability
effectively
transport
medications
or
gene
fragments
tissues
via
passive
active
targeting
processes,
thus
enhancing
treatment
outcomes
while
minimizing
harm
healthy
tissues.
Simultaneously,
context
radiation
sensitization
photothermal
enhance
therapeutic
efficacy
malignant
tumors.
This
review
presents
literature
overview
summary
how
nanotechnology
used
According
oncological
diseases
originating
from
different
systems
body
combining
pathophysiological
features
cancers
at
sites,
we
most
recent
developments
applications.
Finally,
briefly
discuss
prospects
challenges
cancer.
CNS Neuroscience & Therapeutics,
Год журнала:
2024,
Номер
30(5)
Опубликована: Май 1, 2024
Abstract
Gliomas
are
the
most
common
primary
tumors
of
central
nervous
system,
with
glioblastoma
multiforme
(GBM)
having
highest
incidence,
and
their
therapeutic
efficacy
depends
primarily
on
extent
surgical
resection
postoperative
chemotherapy.
The
role
intracranial
blood–brain
barrier
occurrence
drug‐resistant
gene
O6‐methylguanine‐DNA
methyltransferase
have
greatly
limited
chemotherapeutic
agents
in
patients
GBM
made
it
difficult
to
achieve
expected
clinical
response.
In
recent
years,
rapid
development
nanotechnology
has
brought
new
hope
for
treatment
tumors.
Nanoparticles
(NPs)
shown
great
potential
tumor
therapy
due
unique
properties
such
as
light,
heat,
electromagnetic
effects,
passive
targeting.
Furthermore,
NPs
can
effectively
load
drugs,
significantly
reduce
side
effects
improve
efficacy,
showing
chemotherapy
glioma.
this
article,
we
reviewed
mechanisms
glioma
drug
resistance,
physicochemical
NPs,
advances
resistance.
We
aimed
provide
perspectives
Advanced Healthcare Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Май 13, 2024
Current
research
in
cancer
therapy
focuses
on
personalized
therapies,
through
nanotechnology-based
targeted
drug
delivery
systems.
Particularly,
controlled
release
with
nanoparticles
(NPs)
can
be
designed
to
safely
transport
various
active
agents,
optimizing
specific
organs
and
tumors,
minimizing
side
effects.
The
use
of
microfluidics
(MFs)
this
field
has
stood
out
against
conventional
methods
by
allowing
precise
control
over
parameters
like
size,
structure,
composition,
mechanical/biological
properties
nanoscale
carriers.
This
review
compiles
applications
the
production
core-shell
NPs
(CSNPs)
for
therapy,
discussing
versatility
inherent
microchannel
and/or
micromixer
setups
showcasing
how
these
utilized
individually
or
combination,
as
well
technology
allows
development
new
advances
more
efficient
fabrication
nanoformulations.
Recent
biological
studies
have
achieved
an
effective,
safe,
otherwise
unreliable
encapsulants
such
small
interfering
RNA
(siRNA),
plasmid
DNA
(pDNA),
cisplatin
a
result
precisely
tuned
nanocarriers,
showing
that
is
paving
way
innovative
strategies
nanofabrication,
characterized
continuous
high
reproducibility.
Finally,
analyzes
technical,
biological,
technological
limitations
currently
prevent
from
becoming
standard.
Frontiers in Oncology,
Год журнала:
2025,
Номер
14
Опубликована: Янв. 16, 2025
Multiple
Myeloma
(MM)
is
the
second
most
common
malignancy
of
hematopoietic
system,
accounting
for
approximately
10%
all
hematological
malignancies,
and
currently,
there
no
complete
cure.
Existing
research
indicates
that
exosomal
long
non-coding
RNAs
(lncRNAs)
play
a
crucial
regulatory
role
in
initiation
progression
tumors,
involving
various
interactions
such
as
lncRNA-miRNA,
lncRNA-mRNA,
lncRNA-RNA
binding
proteins
(RBP).
Despite
significant
clinical
application
potential
lncRNAs,
this
area
still
faces
challenges
due
to
their
low
abundance
technical
limitations.
To
our
knowledge,
review
first
comprehensively
integrate
elucidate
three
mechanisms
action
lncRNAs
MM,
propose
therapeutic
targets
cases
based
on
these
mechanisms.
We
highlight
latest
advancements
biomarkers
targets,
offering
not
only
comprehensive
analysis
MM
but
also
new
perspectives
methods
future
diagnosis
treatment
multiple
myeloma.
Asian Journal of Pharmaceutical and Clinical Research,
Год журнала:
2025,
Номер
unknown, С. 8 - 26
Опубликована: Фев. 7, 2025
Hepatocellular
carcinoma
(HCC)
represents
a
significant
threat
to
global
health
and
is
responsible
for
mortality
rates
worldwide.
Conventional
treatment
options
such
as
surgery
chemotherapy
have
inherent
limitations.
In
order
remedy
these
deficits,
the
development
of
novel
therapeutic
strategies
essential.
Nanomedicines
shown
promise
in
HCC
they
offer
improved
stability,
controlled
release,
increased
drug
loading
capacity.
This
review
explores
application
nanoconstructs
treatment,
including
active
passive
targeting
strategies.
addition,
liver
cell
approaches,
moieties,
conjugation
chemistry
surface
functionalization
are
investigated.
A
compact
overview
various
approaches
also
given.
Cell Biology and Toxicology,
Год журнала:
2024,
Номер
40(1)
Опубликована: Ноя. 20, 2024
Gastric
cancer
(GC)
is
the
fifth
most
common
worldwide,
particularly
prevalent
in
Asia,
especially
China,
where
both
its
incidence
and
mortality
rates
are
significantly
high.
Meanwhile,
nanotechnology
has
demonstrated
great
potential
treatment
of
GC.
In
particular,
nanodrug
delivery
systems
have
improved
therapeutic
efficacy
targeting
through
various
functional
modifications,
such
as
peptides,
tumor
microenvironment
responsiveness,
instrument-based
methods.
For
instance,
silica
(SiO2)
excellent
biocompatibility
can
be
used
a
drug
carrier,
with
porous
structure
enhancing
loading
capacity.
Polymer
nanoparticles
regulate
release
mechanisms
by
altering
material
composition
preparation
Lipid
efficiently
encapsulate
hydrophilic
drugs
promote
cellular
uptake,
while
carbon-based
biosensors
delivery.
Targets
integrins,
HER2
receptors,
been
to
improve
GC
treatment.
Nanodrug
techniques
not
only
enhance
capabilities
but
also
selectively
target
cells.
Currently,
there
lack
systematic
summarization
synthesis
regarding
relationship
between
treatment,
which
some
extent
hinders
researchers
clinicians
from
searching
for
referencing
related
studies,
thereby
reducing
work
efficiency.
This
study
aims
systematically
summarize
existing
research
on
making
it
easier
professionals
search
reference,
promoting
further
role
their
clinical
applications
review
discusses
functionalized
nanocarriers
recent
years,
including
surface
modifications
targeted
markers,
combination
phototherapy,
chemotherapy,
immunotherapy,
along
advantages
challenges.
It
examines
future
prospects
nanomaterials
The
focuses
combined
application
multiple
modalities,
demonstrating
multimodal
treatments.
Furthermore,
thoroughly
explores
specific
challenges
that
face
biocompatibility,
control,
translation
issues,
providing
outlook
developments.
Additionally,
this
emphasizes
value
feasibility
applications,
contrasting
reviews
focus
basic
research.
Through
these
innovations,
we
offer
new
perspectives
directions
development
ACS Omega,
Год журнала:
2024,
Номер
9(5), С. 5175 - 5192
Опубликована: Янв. 26, 2024
The
coronavirus
disease-19
(COVID-19)
pandemic
has
had
a
significant
impact
on
human
life
worldwide
since
2019.
Specific
vaccines
and
antiviral
agents
are
the
most
effective
means
of
preventing
treating
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
infections.
Additionally,
protective
equipment
early
diagnosis
also
contribute
to
controlling
spread
COVID-19.
utilization
biomaterials
in
medicine
pharmaceuticals
is
crucial
ensure
positive
vaccines,
agents,
equipment.
In
this
review,
we
discuss
application
various
types
biomaterials,
including
polymers,
lipid
nanoparticles,
inorganic
protein-
or
peptide-associated
self-assembled
other
for
vaccine,
treatment,
prevention
Finally,
provide
perspective
future
opportunities
challenges
developing
combat
viral
outbreaks
diseases.
